AbbVie Inc – HealthQuill

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

by HealthQuill
November 11, 2024
0 Comments

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.

Drugs Health Pharma

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

by HealthQuill
October 28, 2024
0 Comments

AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to boost the North Chicago, Illinois-based company’s presence in the psychiatric and neurological disorder segment.

Drugs Health Pharma

AbbVie to acquire Cerevel for $8.7b to bolster neurological treatments

HQ Team December 7, 2023: AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to.

by HealthQuill
December 7, 2023
0 Comments

Pfizer’s last-stage experimental trials for treating multi-drug-resistant bacteria have yielded positive results, the US-based company announced.

Drugs Health Medical Pharma

Pfizer: ’Positive results’ emerge out of multi-drug-resistant trials

HQ Team June 1, 2023: Pfizer’s last-stage experimental trials for treating multi-drug-resistant bacteria have yielded positive results, the US-based company announced. The Phase.